Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks
A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Journal of Pharmaceutical Analysis |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177917301132 |
id |
doaj-6cbe9842df634b47b03fa79956fd031e |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anne-Sophie Fiolet Elise Jandot Pauline Doucey Coralie Crétet Célia Brunel Christine Pivot Jean-Marc Ghigo Christophe Beloin David Lebeaux Fabrice Pirot |
spellingShingle |
Anne-Sophie Fiolet Elise Jandot Pauline Doucey Coralie Crétet Célia Brunel Christine Pivot Jean-Marc Ghigo Christophe Beloin David Lebeaux Fabrice Pirot Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks Journal of Pharmaceutical Analysis |
author_facet |
Anne-Sophie Fiolet Elise Jandot Pauline Doucey Coralie Crétet Célia Brunel Christine Pivot Jean-Marc Ghigo Christophe Beloin David Lebeaux Fabrice Pirot |
author_sort |
Anne-Sophie Fiolet |
title |
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks |
title_short |
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks |
title_full |
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks |
title_fullStr |
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks |
title_full_unstemmed |
Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locks |
title_sort |
long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (edta-na2) solution for catheter locks |
publisher |
Elsevier |
series |
Journal of Pharmaceutical Analysis |
issn |
2095-1779 |
publishDate |
2018-12-01 |
description |
A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of antimicrobial lock solution (ALS) were detailed and completed by a stability study. Stability of ALS was conducted for 12 months in vial (25 °C ± 2 °C, 60% ± 5% relative humidity (RH), and at 40 °C ± 2 °C, RH 75% ± 5%) and for 24 h and 72 h in TIVAP (40 °C ± 2 °C, RH 75% ± 5%). A stability indicating HPLC assay with UV detection for simultaneous quantification of gentamicin sulfate and EDTA-Na2 was developed. ALS was assayed by ion-pairing high performance liquid chromatography (HPLC) needing gentamicin derivatization, EDTA-Na2 metallocomplexation of samples and gradient mobile phase. HPLC methods to separate four gentamicin components and EDTA-Na2 were validated. Efficiency of sterility procedure and conditioning of ALS was confirmed by bacterial endotoxins and sterility tests. Physicochemical stability of ALS was determined by visual inspection, osmolality, pH, and sub-visible particle counting. Results confirmed that the stability of ALS in vials was maintained for 12 months and 24 h and 72 h in TIVAP. Keywords: Gentamicin-EDTA-Na2 loaded antimicrobial lock solution, Pharmaceutical compounding, Stability indicating HPLC assay method, Totally implantable venous access ports |
url |
http://www.sciencedirect.com/science/article/pii/S2095177917301132 |
work_keys_str_mv |
AT annesophiefiolet longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT elisejandot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT paulinedoucey longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT coraliecretet longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT celiabrunel longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT christinepivot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT jeanmarcghigo longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT christophebeloin longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT davidlebeaux longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks AT fabricepirot longtermstabilityofgentamicinsulfateethylenediaminetetraaceticaciddisodiumsaltedtana2solutionforcatheterlocks |
_version_ |
1724171338889822208 |
spelling |
doaj-6cbe9842df634b47b03fa79956fd031e2021-04-02T07:14:44ZengElsevierJournal of Pharmaceutical Analysis2095-17792018-12-0186386393Long-term stability of gentamicin sulfate-ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) solution for catheter locksAnne-Sophie Fiolet0Elise Jandot1Pauline Doucey2Coralie Crétet3Célia Brunel4Christine Pivot5Jean-Marc Ghigo6Christophe Beloin7David Lebeaux8Fabrice Pirot9Service Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, FranceUnité de Génétique des Biofilms, Département de Microbiologie, Institut Pasteur, 28 rue du docteur Roux, F-75724 Paris Cedex 15, France; Service de Microbiologie, Unité Mobile de Microbiologie Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France; Université Paris Descartes, 12 rue de l′Ecole de Médecine, 75270 Paris Cedex 06, FranceService Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, France; Laboratoire de Recherche et Développement de Pharmacie Galénique Industrielle, UMR 5305, Plateforme FRIPHARM,F-69373, Faculté de Pharmacie, Université Claude Bernard Lyon 1, 8, avenue Rockefeller, F-69373 Lyon Cedex 08, France; Corresponding author at: Service Pharmaceutique, Plateforme FRIPHARM, Groupe Hospitalier Centre Edouard Herriot, Hospices Civils de Lyon, 5, Place d′Arsonval, F-69437 Lyon Cedex 03, France.A lock solution composed of gentamicin sulfate (5 mg/mL) and ethylenediaminetetraacetic acid disodium salt (EDTA-Na2, 30 mg/mL) could fully eradicate in vivo bacterial biofilms in totally implantable venous access ports (TIVAP). In this study, fabrication, conditioning and sterilization processes of antimicrobial lock solution (ALS) were detailed and completed by a stability study. Stability of ALS was conducted for 12 months in vial (25 °C ± 2 °C, 60% ± 5% relative humidity (RH), and at 40 °C ± 2 °C, RH 75% ± 5%) and for 24 h and 72 h in TIVAP (40 °C ± 2 °C, RH 75% ± 5%). A stability indicating HPLC assay with UV detection for simultaneous quantification of gentamicin sulfate and EDTA-Na2 was developed. ALS was assayed by ion-pairing high performance liquid chromatography (HPLC) needing gentamicin derivatization, EDTA-Na2 metallocomplexation of samples and gradient mobile phase. HPLC methods to separate four gentamicin components and EDTA-Na2 were validated. Efficiency of sterility procedure and conditioning of ALS was confirmed by bacterial endotoxins and sterility tests. Physicochemical stability of ALS was determined by visual inspection, osmolality, pH, and sub-visible particle counting. Results confirmed that the stability of ALS in vials was maintained for 12 months and 24 h and 72 h in TIVAP. Keywords: Gentamicin-EDTA-Na2 loaded antimicrobial lock solution, Pharmaceutical compounding, Stability indicating HPLC assay method, Totally implantable venous access portshttp://www.sciencedirect.com/science/article/pii/S2095177917301132 |